Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
ARWR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.53 - $39.83
Previous Close$17.84
Volume289.42K
Average Volume (3M)1.04M
Market Cap
$2.19B
Enterprise Value$2.00B
Total Cash (Recent Filing)$367.27M
Total Debt (Recent Filing)$118.09M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 25, 2024EPS Estimate
-$0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.65
Shares Outstanding124,315,274
10 Day Avg. Volume1,072,913
30 Day Avg. Volume1,044,068
Standard Deviation0.20
R-Squared0.06
Alpha-0.00075
Financial Highlights & Ratios
Price to Book (P/B)6.71
Price to Sales (P/S)114.01
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue101.76
Enterprise Value/Gross Profit8.31
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$42.90Price Target Upside145.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentArrowhead's next-gen TRiM platform enables subcutaneous dosing, showing high concentrations of siRNA in the deep brain region, which is a significant advancement over traditional methods.
Pipeline ExpansionArrowhead is expanding its cardiometabolic franchise with plans to advance two obesity candidates to Phase 1/2 programs, supported by preclinical data demonstrating the potential of its TRiM platform.
Trial ResultsPlozasiran treatment led to a statistically significant reduction in the incidence of acute pancreatitis compared to placebo, highlighting its potential as a best-in-class treatment for familial chylomicronemia syndrome.
Bears Say
Debt And R&D SpendingThe equity sell-off was driven by relatively expensive debt financing coincided with higher than expected R&D spend, which is required to support pipeline candidates' moving into and through clinical trials.
Financial PerformanceInvestor focus remains on operational expenditure growth, debt burden, and greater clarity on the ongoing cardiovascular outcomes trial.
Treatment OutcomesPlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if TGs decrease.
---
Ownership Overview
4.46% Insiders
19.89% Mutual Funds
0.03% Other Institutional Investors
50.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $17.53 and its highest was $39.83 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 25, 2024 which is in 46 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.529 by -$0.851.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -$0.97.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,315,280 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.529. Following the earnings report the stock price went down -9.439%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 108M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.90 (145.56% Upside)
$42.90 (145.56% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 280.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.55%
12-Months-Change
Fundamentals
Return on Equity
-154.92%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
ARWR Earnings Call
Q3 2024
0:00 / 0:00
---
ARWR Stock 12 Month Forecast
Average Price Target
$42.90
▲(145.56% Upside)
Technical Analysis
Alnylam Pharma
―
Sarepta Therapeutics
―
Arcturus Therapeutics
―
Ionis Pharmaceuticals
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/37 ratings generated profit
1 Year Average Return
+32.39%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 51.35% of your transactions generating a profit, with an average return of +32.39% per trade.
---